CA2500093A1 - Dna vaccine encoding at least two nonstructural early proteins of papillomavirus - Google Patents

Dna vaccine encoding at least two nonstructural early proteins of papillomavirus Download PDF

Info

Publication number
CA2500093A1
CA2500093A1 CA002500093A CA2500093A CA2500093A1 CA 2500093 A1 CA2500093 A1 CA 2500093A1 CA 002500093 A CA002500093 A CA 002500093A CA 2500093 A CA2500093 A CA 2500093A CA 2500093 A1 CA2500093 A1 CA 2500093A1
Authority
CA
Canada
Prior art keywords
thr
ser
leu
val
glu
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002500093A
Other languages
English (en)
French (fr)
Inventor
Gerald Wayne Gough
Christopher Michael Roberts
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2500093A1 publication Critical patent/CA2500093A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA002500093A 2002-10-03 2003-10-01 Dna vaccine encoding at least two nonstructural early proteins of papillomavirus Abandoned CA2500093A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0222953.2 2002-10-03
GBGB0222953.2A GB0222953D0 (en) 2002-10-03 2002-10-03 Novel Compounds
PCT/EP2003/011158 WO2004031222A2 (en) 2002-10-03 2003-10-01 Dna vaccine encoding at least two nonstructural early proteins of papillomavirus

Publications (1)

Publication Number Publication Date
CA2500093A1 true CA2500093A1 (en) 2004-04-15

Family

ID=9945247

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002500093A Abandoned CA2500093A1 (en) 2002-10-03 2003-10-01 Dna vaccine encoding at least two nonstructural early proteins of papillomavirus

Country Status (21)

Country Link
US (2) US20060165713A1 (https=)
EP (1) EP1546191A2 (https=)
JP (1) JP2006516386A (https=)
KR (1) KR20050050115A (https=)
CN (1) CN100393878C (https=)
AR (1) AR041515A1 (https=)
AU (1) AU2003294672A1 (https=)
BR (1) BR0314986A (https=)
CA (1) CA2500093A1 (https=)
CO (1) CO5580837A2 (https=)
GB (1) GB0222953D0 (https=)
IS (1) IS7775A (https=)
MA (1) MA27474A1 (https=)
MX (1) MXPA05003558A (https=)
NO (1) NO20051561L (https=)
NZ (1) NZ539154A (https=)
PL (1) PL376534A1 (https=)
RU (1) RU2354701C2 (https=)
TW (1) TW200411055A (https=)
WO (1) WO2004031222A2 (https=)
ZA (1) ZA200503201B (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1753687A (zh) 2002-10-29 2006-03-29 科勒制药集团股份有限公司 Cpg寡核苷酸在治疗丙型肝炎病毒感染中的应用
CL2008000249A1 (es) * 2007-01-30 2008-05-30 Transgene Sa Uso de una molecula de acido nucleico que codifica al menos un polipeptido e2 del papilomavirus, un vector o una particula virica infecciosa que la comprenda para tratar una infeccion permanente por papilomavirus causada por al menos un papilomavirus
GB0710538D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Vaccine
JP2013532971A (ja) * 2010-06-25 2013-08-22 バッシボディ アクスイェ セルスカプ ホモ二量体タンパク質コンストラクト
CN107001430A (zh) * 2014-10-24 2017-08-01 哈普威克斯有限责任公司 癌症和皮肤病变治疗
IL260030B2 (en) 2016-01-08 2025-12-01 Nykode Therapeutics ASA Therapeutic anticancer neoepitope vaccine
CA3023022A1 (en) * 2016-05-04 2017-11-09 Transgene Sa Combination therapy with cpg tlr9 ligand
JP2023550480A (ja) * 2020-11-25 2023-12-01 プレシゲン，インコーポレイテッド ヒト乳頭腫ウイルスワクチンおよびｈｐｖ関連疾患のための同ワクチンの使用

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN443995A0 (en) * 1995-07-27 1995-08-17 Csl Limited Papillomavirus polyprotein
HK1056195B (en) * 2000-07-21 2007-06-22 Glaxo Group Limited Codon-optimized papilloma virus sequences
GB0017990D0 (en) * 2000-07-21 2000-09-13 Glaxo Group Ltd Papilloma virus sequences

Also Published As

Publication number Publication date
TW200411055A (en) 2004-07-01
MXPA05003558A (es) 2005-06-03
AR041515A1 (es) 2005-05-18
WO2004031222A2 (en) 2004-04-15
US20060165713A1 (en) 2006-07-27
JP2006516386A (ja) 2006-07-06
BR0314986A (pt) 2005-08-09
NO20051561L (no) 2005-06-02
CN1720261A (zh) 2006-01-11
PL376534A1 (pl) 2006-01-09
IS7775A (is) 2005-03-29
KR20050050115A (ko) 2005-05-27
US20070264283A1 (en) 2007-11-15
CO5580837A2 (es) 2005-11-30
MA27474A1 (fr) 2005-08-01
CN100393878C (zh) 2008-06-11
WO2004031222A3 (en) 2004-08-19
RU2354701C2 (ru) 2009-05-10
RU2005109155A (ru) 2006-03-10
NO20051561D0 (no) 2005-03-23
GB0222953D0 (en) 2002-11-13
EP1546191A2 (en) 2005-06-29
ZA200503201B (en) 2006-06-28
NZ539154A (en) 2007-05-31
AU2003294672A1 (en) 2004-04-23

Similar Documents

Publication Publication Date Title
KR100874552B1 (ko) 코돈-최적화 파필로마 바이러스 서열
Liu et al. Polynucleotide viral vaccines: codon optimisation and ubiquitin conjugation enhances prophylactic and therapeutic efficacy
EP0768893B1 (en) Polynucleotide vaccine for papillomavirus
US20010006639A1 (en) Immunogenic peptides from the HPV E7 protein
AU2001275695A1 (en) Codon-optimized papilloma virus sequences
US20070264283A1 (en) Vaccine
EP1292328A1 (en) Chimeric human papillomavirus (hpv) l1 molecules and uses therefor
AU2001275458A1 (en) Chimeric human papillomavirus (HPV) L1 molecules and uses therefor
EP1305039B1 (en) Stable (fixed) forms of viral l1 capsid proteins, fusion proteins and uses thereof
US7132262B2 (en) Papilloma virus sequences
EP0561885B1 (en) Subunit papillomavirus vaccine
US6183745B1 (en) Subunit papilloma virus vaccine and peptides for use therein
WO2008145745A1 (en) Vaccine against hpv
CA2457890A1 (en) Vaccine using papillomavirus e proteins delivered by viral vector
AU660954B2 (en) Subunit papillomavirus vaccine and peptides for use therein
Deng et al. The preparation of human papillomavirus type 58 vaccine and exploring its biological activity and immunogenicity in vitro
Poláková Gene Immunotherapy of Cancer: DNA Vaccines against HPV 16

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued